Organon & Co. Common Stock vs SK Telecom Co. Ltd. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while SK Telecom Co. Ltd. Common Stock trades at $32.13 (market cap $12.77B). The key difference: SK Telecom Co. Ltd. Common Stock is far larger — about 3.5× Organon & Co. Common Stock's market cap, and SK Telecom Co. Ltd. Common Stock pays the higher dividend (2.82%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and SK Telecom Co. Ltd. Common Stock for 6 Days on average.
| OGN | SKM | |
|---|---|---|
Market Cap | $3.62B | $12.77B |
Volume | 2,892,999 | 1,991,125 |
Sector | Health | Media |
52-Week High | $13.81 | $46.00 |
52-Week Low | $5.70 | $19.68 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $18.85B |
Dividend Yield | 0.58% | 2.82% |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SKM trades at $34.42, up 2.9% today, showing strong earnings momentum with three consecutive quarterly beats. The stock faces technical headwinds with a bearish moving average signal despite oversold RSI conditions. Fundamentally, the company demonstrates robust gross margins of 87.51% but modest net income margins of 4.38%, with recent AI data center spin-offs creating potential value catalysts.
Outlook remains balanced with analyst consensus divided (42.85% Buy, 42.86% Hold) amid AI infrastructure expansion opportunities. Key risks include negative cash flow trends and competitive pressures in wireless communications. The current valuation at 24.39 P/E appears reasonable given growth initiatives, but execution on data center strategy will determine future performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →SK Telecom is a South Korean telecommunications company providing mobile, broadband, and digital services. It also develops services in areas such as AI, cloud, and data centers.
Read more on SKM →